SynthesisAnnals of hematology2024
Rasburicase-induced hemolytic anemia and methemoglobinemia: a systematic review of current reports.
Synthesis in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 11 citations in OpenAlex.
- Methaemoglobinaemia: From pathophysiology to contemporary clinical management.British journal of haematology · 2026Review
- Biochemical deciphering of an Atypical methemoglobinemia.Practical laboratory medicine · 2026Article
- Effects of a Single Intramuscular Dose of Rasburicase on Plasma Uric Acid Concentrations in Fasted and Fed Ball Pythons (Veterinary sciences · 2026Article
- Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics.ACS pharmacology & translational science · 2026Review
- Drug-induced methemoglobinemia in a child with comorbidity and polypragmasia: Case report.The International journal of risk & safety in medicine · 2026Article
- A Rare Case of Acute Hemolysis After Rasburicase Infusion.Journal of the advanced practitioner in oncology · 2026Article
- Acute Hemolytic Anemia Following Rasburicase in a Very Late Post-Transplant Relapse of Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2026Article
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
- The Use of Single Dose of Rasburicase for the Prophylaxis and Treatment of Tumor Lysis Syndrome in Pediatric Patients: A Narrative Review.Hematology reports · 2025Review
- Exploiting artificial intelligence in precision oncology: an updated comprehensive review.Journal of translational medicine · 2025Review
- Methylene blue in the critical care setting.World journal of critical care medicine · 2025Review
- Glucose-6-phosphate dehydrogenase deficiency induced hemolytic anemia and methemoglobinemia: a case report in a 7 -year-old female patient.Italian journal of pediatrics · 2025Article
- Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.Frontiers in endocrinology · 2025Review
- Tumour lysis syndrome.Nature reviews. Disease primers · 2024Review
- Preliminary Investigation into the Prevalence of G6PD Deficiency in a Pediatric African American Population Using a Near-Patient Diagnostic Platform.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the FDA's approval of rasburicase use for treatment of tumor lysis syndrome (TLS), multiple cases of rasburicase-induced methemoglobinemia and hemolytic anemia have been reported among patients with G6PD deficiency. This study aims to provide a systematic review of cases reporting such adverse reactions to rasburicase. A literature review of published cases in PubMed, Embase, Cochrane, and Web of Science was conducted. Descriptive studies reporting cases of rasburicase-induced methemoglobinemia and/or hemolytic anemia in English were analyzed and summarized in this study. Forty-three cases, including a case from our institution, were included in this study. Most cases (60.5%) received rasburicase for TLS treatment. Almost all patients (93.8%) were tested for G6PD after rasburicase administration. The median time to symptom onset was 24 h. The median methemoglobin level was 10%, peaking after a median of 24 h. The median hemoglobin nadir was 6.1 g/dL, and most patients (n = 32) required blood transfusion. Out of 39 cases with reported outcomes, 35 patients (89.7%) recovered, while four patients (three females and one male) died. The median time to recovery was 4.5 days while the median time to death was 8 days. Screening for G6PD deficiency among high-risk patients is important but not practical in acutely severe settings. When prior screening for G6PD deficiency is not feasible, close monitoring for methemoglobinemia and hemolytic anemia is recommended. Exchange transfusion is increasingly reported as a potentially successful therapeutic modality. Ascorbic acid may provide limited benefits. Methylene blue should be avoided as it may exacerbate hemolysis among these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.